|
PACRGL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.99684713209081E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.4397372183339E-12 |
| Normal-vs-Stage2 |
2.35910180279575E-11 |
| Normal-vs-Stage3 |
2.36866082303777E-12 |
| Normal-vs-Stage4 |
1.00808250635964E-13 |
| Stage1-vs-Stage2 |
2.374200E-01 |
| Stage1-vs-Stage3 |
4.794000E-01 |
| Stage1-vs-Stage4 |
1.272750E-01 |
| Stage2-vs-Stage3 |
5.568400E-01 |
| Stage2-vs-Stage4 |
8.400400E-01 |
| Stage3-vs-Stage4 |
3.706000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93856042329799E-12 |
| Normal-vs-AfricanAmerican |
1.58649999999483E-05 |
| Normal-vs-Asian |
7.15639991710759E-10 |
| Caucasian-vs-AfricanAmerican |
2.322800E-01 |
| Caucasian-vs-Asian |
4.048000E-01 |
| AfricanAmerican-vs-Asian |
6.243800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.1641356201817E-14 |
| Normal-vs-Female |
2.80631073934501E-12 |
| Male-vs-Female |
8.234200E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.22262266556118E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.89481763612775E-12 |
| Normal-vs-Age(81-100Yrs) |
7.623500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.689000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.837200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.000600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.985800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.202600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.968180E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.440200E-02 |
| Classical-VS-Follicular |
2.469000E-01 |
| Classical-VS-Other |
2.601000E-01 |
| Classical-VS-Normal |
4.16300327543695E-11 |
| Tall-VS-Follicular |
3.662800E-01 |
| Tall-VS-Other |
8.902400E-01 |
| Tall-VS-Normal |
7.46858130895589E-12 |
| Follicular-VS-Other |
6.119800E-01 |
| Follicular-VS-Normal |
3.34499095089313E-12 |
| Other-VS-Normal |
3.578700E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
2.2154500456395E-12 |
| N0-vs-N1 |
4.526200E-01 |
|
|
